dr reddy's glp-1 drugs portfolio 2025 Dr. Reddy's-Nestlé Health Science Launch Celevida® GLP+ to Support Patients on GLP-1/GIP Therapy Complete Guide to GLP-1 Medications
Description
Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes
While GLP-1 receptor agonists are powerful tools for weight loss, maintaining lean muscle is essential for overall health, metabolism, and long-term results
The difference between 8mg and 12mg is minimal
After 108 weeks, changes in UACR from baseline with lixisenatide were 1.69% [(95% CI: 11.69 to 8.30), p=0.7398] in patients with normoalbuminuria, 21.10% [(95% CI: 42.25 to 0.04), p=0.0502] in patients with microalbuminuria, and 39.18% [(95% CI: 6853 to 984), p=0.0070] in patients with macroalbuminuria
Wang T, Hong JL, Gower EW, et al
Natural Products and Combinatorial Chemistry: Back to the Future
